GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultragenyx Pharmaceutical Inc (MEX:RARE) » Definitions » Cyclically Adjusted PS Ratio

Ultragenyx Pharmaceutical (MEX:RARE) Cyclically Adjusted PS Ratio : 11.82 (As of Jun. 23, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Ultragenyx Pharmaceutical Cyclically Adjusted PS Ratio?

As of today (2024-06-23), Ultragenyx Pharmaceutical's current share price is MXN751.98. Ultragenyx Pharmaceutical's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was MXN63.62. Ultragenyx Pharmaceutical's Cyclically Adjusted PS Ratio for today is 11.82.

The historical rank and industry rank for Ultragenyx Pharmaceutical's Cyclically Adjusted PS Ratio or its related term are showing as below:

MEX:RARE' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 8.75   Med: 12.4   Max: 28.85
Current: 10.02

During the past years, Ultragenyx Pharmaceutical's highest Cyclically Adjusted PS Ratio was 28.85. The lowest was 8.75. And the median was 12.40.

MEX:RARE's Cyclically Adjusted PS Ratio is ranked worse than
67.72% of 505 companies
in the Biotechnology industry
Industry Median: 5.25 vs MEX:RARE: 10.02

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Ultragenyx Pharmaceutical's adjusted revenue per share data for the three months ended in Mar. 2024 was MXN21.430. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is MXN63.62 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Ultragenyx Pharmaceutical Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Ultragenyx Pharmaceutical's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultragenyx Pharmaceutical Cyclically Adjusted PS Ratio Chart

Ultragenyx Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 13.78 12.47

Ultragenyx Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.41 12.62 9.49 12.47 11.82

Competitive Comparison of Ultragenyx Pharmaceutical's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Ultragenyx Pharmaceutical's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ultragenyx Pharmaceutical's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ultragenyx Pharmaceutical's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Ultragenyx Pharmaceutical's Cyclically Adjusted PS Ratio falls into.



Ultragenyx Pharmaceutical Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Ultragenyx Pharmaceutical's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=751.98/63.62
=11.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ultragenyx Pharmaceutical's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Ultragenyx Pharmaceutical's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=21.43/131.7762*131.7762
=21.430

Current CPI (Mar. 2024) = 131.7762.

Ultragenyx Pharmaceutical Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 0.000 99.792 0.000
201603 0.000 100.470 0.000
201606 0.008 101.688 0.010
201609 0.054 101.861 0.070
201612 0.003 101.863 0.004
201703 0.000 102.862 0.000
201706 0.000 103.349 0.000
201709 0.085 104.136 0.108
201712 1.099 104.011 1.392
201803 3.952 105.290 4.946
201806 5.046 106.317 6.254
201809 4.373 106.507 5.411
201812 6.290 105.998 7.820
201903 6.625 107.251 8.140
201906 8.065 108.070 9.834
201909 8.826 108.329 10.736
201912 11.609 108.420 14.110
202003 14.680 108.902 17.764
202006 23.295 108.767 28.223
202009 29.656 109.815 35.587
202012 28.149 109.897 33.753
202103 30.278 111.754 35.703
202106 25.608 114.631 29.438
202109 24.734 115.734 28.162
202112 24.943 117.630 27.943
202203 22.895 121.301 24.872
202206 25.705 125.017 27.095
202209 26.044 125.227 27.406
202212 28.720 125.222 30.223
202303 25.742 127.348 26.637
202306 26.190 128.729 26.810
202309 23.833 129.860 24.185
202312 26.626 129.419 27.111
202403 21.430 131.776 21.430

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Ultragenyx Pharmaceutical  (MEX:RARE) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Ultragenyx Pharmaceutical Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Ultragenyx Pharmaceutical's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ultragenyx Pharmaceutical (MEX:RARE) Business Description

Traded in Other Exchanges
Address
60 Leveroni Court, Novato, CA, USA, 94949
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.